CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial
CD27 agonist antibodies mediate clinical responses through intratumoral stimulation in B-cell malignancies: multicenter RiVa trial
Purpose: varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show that agonistic CD27 antibodies can activate intratumoral T-cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e. rituximab, in B-cell lymphoma. This clinical trial evaluated the safety and efficacy of rituximab and varlilumab in patients with previously treated B-cell non-Hodgkin lymphoma (B-NHL).
Patient and methods: this multicenter phase IIa trial recruited patients with relapsed or refractory CD20+ B-NHL. Patients were randomized to Arm A or B. All received rituximab on Day 1 of Cycles1-6, and varlilumab on Day 2 (Arm A) or Day 8 (Arm B) of Cycle 1, and Day 2 of Cycles 3 and 5. Tumor biopsies were collecting pre-treatment and on-treatment (after varlilumab in Arm A and before varlilumab in Arm B). The primary objective was to assess safety and anti-tumor activity.
Results: twenty-seven participants were evaluable, with modest overall response and disease control rates of 15.4% (4/27) and 38.8% (8/27), respectively. Intratumoral bulk RNA sequencing analysis demonstrated that adding varlilumab to rituximab enhanced CD4+ T-cell infiltration and increased T- and innate-cell signatures; inflamed tumor signatures were observed pre-treatment in responders. Single-cell analysis further showed that higher levels of CD27-expressing T and NK cells, along with activated γδ T-cell signatures, were associated with response, whereas CD27-expressing B cells correlated with non-response.
Conclusions: rituximab and varlilumab show modest activity. However, CD27 agonist antibodies may elicit meaningful anti-tumor responses when tumors express sufficient intratumoral targets and exhibit existing immune priming.
Buermann, Lara E.
953ffde8-80f4-4bc7-b36b-0502d1e3ff82
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Rose-Zerilli, Matthew J.J.
08b3afa4-dbc2-4c0d-a852-2a9f33431199
Thorne, Kerensa
21a60886-12d9-4ace-b9cd-cf0f64aca53d
Coleman, Adam
49cf504d-6f2b-422b-9c3a-17eb5d5d6a85
Turaj, Anna H.
fbbc48ea-28cf-4db7-ae4a-c16ce7b3857a
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Wignall, Christopher
0fd9e11b-8f96-467f-810c-041bbfca40bc
Keyworth, Nicole
3040ee74-31cf-4cbd-91ef-3223367f7253
Konn, Zoe
525b4648-7c88-488a-aefa-0018ac485eb4
McKay, Pamela
0d63fcec-2881-4115-8a10-ff0f1033fe3c
Osborne, Wendy L.
c8ba0fc6-58eb-4ce3-ab6a-cf97b9beae01
Linton, Kim
e0291ae0-f9be-4a0d-81ef-949d46f9a661
Medd, Patrick G.
d84d8016-e33b-491c-9d20-490532ee72f0
Lown, Robert
74f3fa03-c54a-4fda-8989-34524b75b201
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Collins, Graham P.
383f579f-8748-4d35-9b60-74508fdcda90
Keler, Tibor
38add6e3-58be-4bc4-a9df-ba10c9e1ae1e
Yellin, Michael J.
cbfdf268-6282-4eeb-85d4-f709bfcfad43
Gentles, Andrew James
54d57537-0f70-4c9f-a8b1-166fa30c9434
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Buermann, Lara E.
953ffde8-80f4-4bc7-b36b-0502d1e3ff82
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Rose-Zerilli, Matthew J.J.
08b3afa4-dbc2-4c0d-a852-2a9f33431199
Thorne, Kerensa
21a60886-12d9-4ace-b9cd-cf0f64aca53d
Coleman, Adam
49cf504d-6f2b-422b-9c3a-17eb5d5d6a85
Turaj, Anna H.
fbbc48ea-28cf-4db7-ae4a-c16ce7b3857a
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Wignall, Christopher
0fd9e11b-8f96-467f-810c-041bbfca40bc
Keyworth, Nicole
3040ee74-31cf-4cbd-91ef-3223367f7253
Konn, Zoe
525b4648-7c88-488a-aefa-0018ac485eb4
McKay, Pamela
0d63fcec-2881-4115-8a10-ff0f1033fe3c
Osborne, Wendy L.
c8ba0fc6-58eb-4ce3-ab6a-cf97b9beae01
Linton, Kim
e0291ae0-f9be-4a0d-81ef-949d46f9a661
Medd, Patrick G.
d84d8016-e33b-491c-9d20-490532ee72f0
Lown, Robert
74f3fa03-c54a-4fda-8989-34524b75b201
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Collins, Graham P.
383f579f-8748-4d35-9b60-74508fdcda90
Keler, Tibor
38add6e3-58be-4bc4-a9df-ba10c9e1ae1e
Yellin, Michael J.
cbfdf268-6282-4eeb-85d4-f709bfcfad43
Gentles, Andrew James
54d57537-0f70-4c9f-a8b1-166fa30c9434
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196